Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 69, No 2 (2018)
Original paper
Submitted: 2017-10-22
Accepted: 2017-11-05
Published online: 2017-12-20
View PDF Download PDF file
Get Citation

Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia

Lucyna Siemińska1, Artur Borowski2, Bogdan Marek1, Mariusz Nowak1, Dariusz Kajdaniuk1, Jakub Warakomski1, Beata Kos-Kudła1
DOI: 10.5603/EP.a2018.0006
·
Pubmed: 29465157
·
Endokrynol Pol 2018;69(2):120-127.
Affiliations
  1. Department of Pathophysiology and Endocrinology, School of Medicine with the Division of Densitry in Zabrze, Medical University of Silesia, plac Traugutta 2, 41-800 Zabrze, Poland
  2. The Silesia Urology Centre Urovita, Chorzów, Poland

open access

Vol 69, No 2 (2018)
Original Paper
Submitted: 2017-10-22
Accepted: 2017-11-05
Published online: 2017-12-20

Abstract

Introduction: Obesity and prostate cancer are related, but the causal relationship remains unknown. The aim of the study was to compare concentrations of leptin, adiponectin and chemerin in patients with prostate cancer and benign prostate hyperplasia and to examine associations of the adipokines with the grade of prostate cancer, interleukin-6 (IL-6), insulin resistance and anthropometric and metabolic variables. Material and methods: The study group consisted of 140 men divided into two groups: I- prostate cancer (n=74) and II- with benign hyperplasia (n=66). Serum leptin, adiponectin, chemerin, IL-6 and metabolic profile were measured. Considering histological differentiation prostate cancer patients were divided into 3 subgroups: well differentiated (Gleason score ≤ 6), moderately differentiated subgroup (Gleason 7), and poorly differentiated (Gleason ≥8). Results: There were no differences between groups in BMI, waist circumference, HOMA-I, serum levels of total cholesterol, glucose, triglycerides, adiponectin, leptin and chemerin. However, the concentrations of PSA, leptin-to-adiponectin ratio and IL-6 were significantly higher in cancer group compared with benign hyperplasia group. In the poorly differentiated cancer subgroup, subjects had higher PSA, leptin, chemerin, IL-6 and triglycerides concentrations. Overweight and obese men with prostate cancer were more likely to have moderately or poorly differentiated cancer than those with normal BMI. In the all men serum adiponectin was significantly correlated with HOMA-I, BMI, glucose, triglycerides, cHDL. There were significant correlations between leptin and BMI, HOMA-I, waist, glucose, triglycerides and cHDL. Among all the participants we observed associations between chemerin and waist as well as triglycerides. In prostate cancer patients chemerin correlated with IL-6 and leptin. We measured significant positive correlations between Gleason score and chemerin and leptin concentrations. There was a positive correlation between adiponectin and PSA levels in all men, as well as in cancer group. Conclusion: Leptin-to-adiponectin ratio and IL-6 were elevated in men with prostate cancer. Leptin, chemerin and IL-6 were associated with Gleason score. The relationships between leptin, chemerin and IL-6 were dependent on each other. Overweight and obese men had a higher Gleason score.

Abstract

Introduction: Obesity and prostate cancer are related, but the causal relationship remains unknown. The aim of the study was to compare concentrations of leptin, adiponectin and chemerin in patients with prostate cancer and benign prostate hyperplasia and to examine associations of the adipokines with the grade of prostate cancer, interleukin-6 (IL-6), insulin resistance and anthropometric and metabolic variables. Material and methods: The study group consisted of 140 men divided into two groups: I- prostate cancer (n=74) and II- with benign hyperplasia (n=66). Serum leptin, adiponectin, chemerin, IL-6 and metabolic profile were measured. Considering histological differentiation prostate cancer patients were divided into 3 subgroups: well differentiated (Gleason score ≤ 6), moderately differentiated subgroup (Gleason 7), and poorly differentiated (Gleason ≥8). Results: There were no differences between groups in BMI, waist circumference, HOMA-I, serum levels of total cholesterol, glucose, triglycerides, adiponectin, leptin and chemerin. However, the concentrations of PSA, leptin-to-adiponectin ratio and IL-6 were significantly higher in cancer group compared with benign hyperplasia group. In the poorly differentiated cancer subgroup, subjects had higher PSA, leptin, chemerin, IL-6 and triglycerides concentrations. Overweight and obese men with prostate cancer were more likely to have moderately or poorly differentiated cancer than those with normal BMI. In the all men serum adiponectin was significantly correlated with HOMA-I, BMI, glucose, triglycerides, cHDL. There were significant correlations between leptin and BMI, HOMA-I, waist, glucose, triglycerides and cHDL. Among all the participants we observed associations between chemerin and waist as well as triglycerides. In prostate cancer patients chemerin correlated with IL-6 and leptin. We measured significant positive correlations between Gleason score and chemerin and leptin concentrations. There was a positive correlation between adiponectin and PSA levels in all men, as well as in cancer group. Conclusion: Leptin-to-adiponectin ratio and IL-6 were elevated in men with prostate cancer. Leptin, chemerin and IL-6 were associated with Gleason score. The relationships between leptin, chemerin and IL-6 were dependent on each other. Overweight and obese men had a higher Gleason score.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

obesity, prostate cancer, adiponectin, leptin, chemerin, interleukin-6

About this article
Title

Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia

Journal

Endokrynologia Polska

Issue

Vol 69, No 2 (2018)

Article type

Original paper

Pages

120-127

Published online

2017-12-20

Page views

3229

Article views/downloads

1693

DOI

10.5603/EP.a2018.0006

Pubmed

29465157

Bibliographic record

Endokrynol Pol 2018;69(2):120-127.

Keywords

obesity
prostate cancer
adiponectin
leptin
chemerin
interleukin-6

Authors

Lucyna Siemińska
Artur Borowski
Bogdan Marek
Mariusz Nowak
Dariusz Kajdaniuk
Jakub Warakomski
Beata Kos-Kudła

References (38)
  1. De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012; 61(3): 560–570.
    CrossRefPubMed
  2. Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, et al. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne). 2014; 5: 65.
    CrossRefPubMed
  3. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612): 569–578.
    CrossRefPubMed
  4. Azevedo A, Cunha V, Teixeira AL, et al. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011; 2(12): 384–396.
    CrossRefPubMed
  5. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001; 159(6): 2159–2165.
    CrossRefPubMed
  6. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
    PubMed
  7. Ibarra-Reynoso Ld, Pisarchyk L, Pérez-Luque EL, et al. Whole-body and hepatic insulin resistance in obese children. PLoS One. 2014; 9(11): e113576.
    CrossRefPubMed
  8. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17): 1625–1638.
    CrossRefPubMed
  9. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015; 16(1): 36–46.
    CrossRefPubMed
  10. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013; 63(5): 800–809.
    CrossRefPubMed
  11. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007; 109(4): 675–684.
    CrossRefPubMed
  12. Tilki D, Schlenker B, John M, et al. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol. 2011; 29(5): 508–514.
    CrossRefPubMed
  13. Kim H, Kalchman I, Santiago-Jiménez M, et al. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer. 2017; 123(12): 2240–2247.
    CrossRefPubMed
  14. Webber L. Projected incidence of overweight and obesity and related disease incidence across Poland. Cent Eur J Public Health. 2014; 22(1): 17–23.
    CrossRefPubMed
  15. Siemińska L. [Adipose tissue. Pathophysiology, distribution, sex differences and the role in inflammation and cancerogenesis]. Endokrynol Pol. 2007; 58(4): 330–342.
    PubMed
  16. Boguszewski CL, Boguszewski MC, Kopchick JJ. Growth hormone, insulin-like growth factor system and carcinogenesis. Endokrynol Pol. 2016; 67(4): 414–426.
    CrossRefPubMed
  17. Dutta D, Ghosh S, Pandit K, et al. Leptin and cancer: Pathogenesis and modulation. Indian J Endocrinol Metab. 2012; 16(Suppl 3): S596–S600.
    CrossRefPubMed
  18. Cioffi JA, Shafer AW, Zupancic TJ, et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med. 1996; 2(5): 585–589.
    CrossRefPubMed
  19. Stattin P, Söderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001; 86(3): 1341–1345.
    CrossRefPubMed
  20. Lagiou P, Signorello LB, Trichopoulos D, et al. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer. 1998; 76(1): 25–28, doi: 10.1002/(sici)1097-0215(19980330)76:1<25::aid-ijc5>3.0.co;2-#.
    PubMed
  21. Lai GY, Giovannucci EL, Pollak MN, et al. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control. 2014; 25(5): 625–632.
    CrossRefPubMed
  22. Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010; 56(1): 34–43.
    CrossRefPubMed
  23. Mistry T, Digby JE, Desai KM, et al. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007; 52(1): 46–53.
    CrossRefPubMed
  24. Chung TD, Yu JJ, Spiotto MT, et al. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 1999; 38(3): 199–207, doi: 10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h.
    PubMed
  25. Shariat SF, Kattan MW, Traxel E, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004; 10(6): 1992–1999.
    CrossRefPubMed
  26. Katira A, Tan PH. Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med. 2016; 13(1): 101–119.
    CrossRefPubMed
  27. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007; 16(2): 308–313.
    CrossRefPubMed
  28. Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urology. 2005; 65(6): 1168–1172.
    CrossRefPubMed
  29. Arisan ED, Arisan S, Atis G, et al. Serum adipocytokine levels in prostate cancer patients. Urol Int. 2009; 82(2): 203–208.
    CrossRefPubMed
  30. Housa D, Vernerová Z, Herácek J, et al. Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res. 2008; 57(3): 451–458.
    PubMed
  31. Huang M, Koizumi A, Narita S, et al. Diet-induced alteration of fatty acid synthase in prostate cancer progression. Oncogenesis. 2016; 5: e195.
    CrossRefPubMed
  32. Ikeda A, Nakagawa T, Kawai K, et al. Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer. Prostate Int. 2015; 3(3): 87–92.
    CrossRefPubMed
  33. Freedland SJ, Sokoll LJ, Platz EA, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol. 2005; 174(4 Pt 1): 1266–1270.
    CrossRefPubMed
  34. Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006; 15(7): 1331–1335.
    CrossRefPubMed
  35. Tewari R, Rajender S, Natu SM, et al. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study. Cytokine. 2013; 63(2): 130–134.
    CrossRefPubMed
  36. Kappelle PJ, Dullaart RPF, van Beek AP, et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case-control study. Eur J Intern Med. 2012; 23(8): 755–759.
    CrossRefPubMed
  37. Xu CH, Yang Y, Wang YC, et al. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer. Oncotarget. 2017; 8(14): 22483–22489.
    CrossRefPubMed
  38. Wang C, Wu WKK, Liu X, et al. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides. 2014; 51: 131–138.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl